Peer-reviewed medical journal articles on cluster headache and related conditions.
We have tried to link directly to PDF copies of articles where available for online viewing or download. In some cases, links may be directed to the Abstract only. These articles may require a subscription or one-time purchase in order to access to the journal article. Fees vary. For free or low-cost access to journal articles, please visit patientAccess, PubMed Central, or SpringerLink.
CHSG is not responsible for any fees incurred nor does it receive any payment, royalty, commission, or other compensation as a result of these links.
Article topics
- Calcitonin gene-related peptide and migraine June 1, 2015This article highlights the evidence behind the role of CGRP in migraine and the state of CGRP-based mechanism treatment development. We present a summary of the evidence base behind CGRP in migraine pathophysiology and the novel CGRP mechanism drugs and their potential future contribution to migraine management in our clinical practice.
- CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment May 19, 2015Recently developed calcitonin gene-related peptide (CGRP) receptor antagonistic molecules have shown promising results in clinical trials for acute treatment of migraine attacks. Drugs from the gepant class of CGRP receptor antagonists are effective and do not cause vasoconstriction, one of the major limitations in the use of triptans. However their use had to be discontinued ...
- CGRP Mechanism Antagonists and Migraine Management May 1, 2015Migraine is a complex disorder of the brain that is common and highly disabling. As understanding of the neural pathways has advanced, and it has become clear that the vascular hypothesis does not explain the disorder, new therapeutic avenues have arisen. One such target is calcitonin gene-related peptide (CGRP)-based mechanisms. CGRP is found within the ...
- TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine March 1, 2015Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide whose involvement in migraine pathophysiology is well established. Originally migraine was believed to be a disease of the vasculature, but research has highlighted this to be a disease of the brain with CGRP playing an important role. While targeting CGRP using small molecule antagonists against the receptor ...
- The Neuropsychology of Cluster Headache: Cognition, Mood, Disability, and Quality of Life of Patients With Chronic and Episodic Cluster Headache February 17, 2015Cluster headache (CH) is commonly regarded as one of the most disabling headache conditions, and referred to as one of the most painful conditions known to humankind. Although there has been some research indicating the severe impact of CH, there is little comprehensive evidence of its impact on quality of life, disability, mood, and cognitive ...
- High sensitivity C-reactive protein and cerebral white matter hyperintensities on magnetic resonance imaging in migraine patients January 16, 2015Migraine is a common headache disorder that may be associated with vascular disease and cerebral white matter hyperintensities (WMHs) on magnetic resonance imaging (MRI) scan. High sensitivity C-reactive protein (hs-CRP) is a marker of inflammation that may predict subclinical atherosclerosis. However, the relation between migraine, vascular risks, and WMHs is unknown. We evaluated hs-CRP levels ...
- A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine January 1, 2015Objective: To determine if repetitive sphenopalatine ganglion (SPG) blocks with 0.5% bupivacaine delivered through the Tx360® are superior in reducing pain associated with chronic migraine (CM) compared with saline.
- Site of effect of LY2951742 for migraine prophylaxis January 1, 2015In The Lancet Neurology, David Dodick and colleagues1 report an important study of treatment in migraine prophylaxis: parenteral administration of LY2951742, a monoclonal antibody to calcitonin gene-related peptide (CGRP). Mean decrease from baseline in migraine days in 4 weeks was higher in patients given LY2951742 (4·2) than in those given placebo (3·0; p=0·003).1 Results of other trials that ...
- Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine January 1, 2015Migraine is a neurological disorder that manifests as a debilitating headache associated with altered sensory perception. The neuropeptide calcitonin gene-related peptide (CGRP) is now firmly established as a key player in migraine. Clinical trials carried out during the past decade have proved that CGRP receptor antagonists are effective for treating migraine, and antibodies to the ...
- Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial October 5, 2014In this randomised, double-blind, placebo-controlled, exploratory, proof-of-concept phase 2 trial, patients aged 18–55 years with five to 14 migraine days per 28-day period were randomly assigned (1:1) via an interactive web response system to receive an intravenous dose of ALD403 1000 mg or placebo. Site investigators, patients, and the sponsor were masked to treatment allocation ...